SRF and neoplasm: SRF not only exhibited its direct anti-proliferative activity in cell based assays (KB-3-1 and KB-V1), but also demonstrated an anti-tumor activity in vivo in human HCT15-implanted xenografts with an effective dose of SRF (20 mg/kg/day in mice) [Figure 6].